Ce12halalgia. Effectiveness of oral diclofenac in the acute treatment of common migraine attacks: a double-blind study versus placebo
|
|
- Colin Singleton
- 6 years ago
- Views:
Transcription
1 Effectiveness of oral diclofenac in the acute treatment of common migraine attacks: a double-blind study versus placebo Helene Massiou, Dominique Serrurier, Odile Lasserre, Marie-Germaine Bousser Ce12halalgia Massiou H, Serrurier D, Lasserre 0, Bousser M-G. Effectiveness of oral diclofenac in the acute treatment of common migraine attacks: a double-blind study versus placebo. Cephalalgia 1991;11: Oslo. ISSN In a multicentre double-blind cross-over trial, oral diclofenac at a dose of 50 mg to 100 mg was compared to placebo in the acute treatment of migraine attacks. A hundred and seven patients suffering from migraine without aura were included, and 91 were analysed for efficacy; they had to treat four successive attacks-two with diclofenac and two with placebo. Diclofenac was significantly more effective than placebo (p < 0.05) on the main judgement parameter, which was the number of attacks aborted within 2 h of drug intake, as well as on the following secondary parameters: the necessity for an escape medication and the evaluation of global efficacy. Diclofenac was well tolerated. This trial demonstrates the efficacy of diclofenac in the acute treatment of migraine attacks. It confirms the good clinical relevance of the main judgement parameter chosen, which is the one recommended by the International Headache Society, but appears to be a severe one in terms of successes. D Clinical trial, dicloienac, migraine, placebo Helene Massiou, Marie-Germaine Bousser, Department of Neurology, Hopital Saint-Antoine, F Paris Cedex 12, France; Dominique Serrurier, Odile Lasserre, LaboratoiresCiba-Geigy, Medical Department, BP 308, F Rueil-Malmaison Cedex, France; Correspondence to Dominique Serrurier; Accepted 11 January 1991 Since the 1970s, several non-steroidal anti-inflammatory drugs have been studied in clinical trials in order to evaluate their therapeutic efficacy in migraine attacks, and found more effective than placebo in this indication (1-13). There are, however, important discrepancies between the methodologies used in these trials, especially concerning the judgement criteria on efficacy, which make their results difficult to compare. In 1987, Del Bene et al. (12) demonstrated the efficacy of intramuscular diclofenac sodium in the treatment of migraine attack in a double-blind study versus placebo. We decided to study oral diclofenac in this indication in a controlled trial versus placebo. Special attention was focused on methodology by taking into account the proposed guidelines of the International Headache Society for controlled trials of drugs in migraine, which were in process at the time we began the trial. Patients and methods Patients The study was a multicentre double-blind, placebo controlled, cross-over trial. Patients suffering from migraine without aura for at least two years, with 2 to 8 attacks monthly, were recruited after having given their informed consent according to the Declaration of Helsinki. Excluded from the study were patients who: (1) had more than lout of 4 attacks on waking; (2) had other types of migraine or other headaches, including migraine with aura and tension type headaches; (3) had a history of peptic ulcer; (4) had an allergy to non-steroidal anti-inflammatory drugs. Prophylactic treatments of migraine (except for non-steroidal anti-inflammatory drugs and aspirin), oral contraceptives and minor tranquilizers were allowed, if taken for at least two months before the beginning of the study, and not modified during the trial. Study design A cross-over design was chosen with two attacks treated by the same drug in order to reduce intrapatient variability, as recommended by Tfelt-Hansen and Olesen (14). The study was conducted in seven centres in France. Each patient had to treat four successive attacks, two with diclofenac and two with placebo. Patients were allocated to receive either diclofenac or placebo for the first two attacks and the other treatment for the last two attacks using a computergenerated randomization list stratified by the investigator centre. Each tablet contained either 50 mg of entericcoated diclofenac or matching placebo, the package being labelled with a research code number. The first tablet had to be taken in the 30 min following the onset of headache; a second tablet could be taken 1 h later if relief was judged insufficient by the patient. Escape medication (excluding non-steroidal
2 60 H Massiou et al. anti-inflammatory drugs and aspirin) was allowed 2 h after the first tablet intake. Table 1. Disposition of patients. CEPHALALGIA 11 (1991) Group I Group II Total Evaluations Therapeutic efficacy was assessed from the patient record forms. For each attack the patient recorded: the date and time of onset of the migraine attack, the time of test and escape medication intake, the intensity of headache on visual analogue scales just before the first tablet intake, 1 h, 2 hand 3 h later, the presence of nausea or vomiting, the duration of the attack and their average subjective evaluation of drug efficacy. Patients were also required to describe side effects, whose intensity and relation to the test drug were evaluated by the investigator. Statistical analysis Statistical analysis was conducted using the method described by Hills and Armitage (15) for the two-period cross-over clinical trial. Because two attacks were treated successively with the same drug in each period, the average of the two attacks was used in the analysis for interval and ordinal variables such as intensity, duration and efficacy assessment. Tests of interaction, period and treatment effects were then performed by appropriate comparisons between the two groups of randomization using a two-sided Student's t-test (duration, intensity) or Wilcoxon rank sum test (assessments on ordinal scale). Binary variables such as success/failure or presence/absence of a sign or a symptom were coded 0/1 for each attack and the number of Is in each period was used in the analysis. Differences between periods range from - 2 to +2, and groups were compared using a two-sided Wilcoxon rank sum test. When one of the two attacks had not been treated in a given period, it was assumed to be a failure for analysis on binary variables. However, an analysis on patients who treated the four attacks was also performed for the main efficacy parameter. No period effect nor treatment by period interaction was ever found to be significant at the 5% level. Because of the limited power of the interaction test, it does not necessarily imply absence of carryover from one period to the other. Nevertheless, there is no reason to suspect pharmacological carryover in this study, since the interval between attacks was long enough to ensure elimination of the test drug. Results Patient population A hundred and seven patients were included in Randomized Lost to follow-up Available for analysis Treated only one or two attacks Personal report form missing Cross-over analysis Fourth attack not treated Four treated attacks Four successive attacks treated in the following order: Group I: Diclofenac - diclofenac - placebo - placebo. Group II: Placebo - placebo - diclofenac - diclofenac. the trial, but three were lost to follow-up, permitting analysis on 104. Eleven of them treated only one or two attacks, i.e. used only one drug, and an additional two did not fill out their personal report form, allowing cross-over analysis on 91 patients. Eight out of the 91 did not treat the fourth attack but could be kept in the cross-over analysis since they used both treatments for at least one attack. These data are summarized in Table 1. Altogether the 104 analysed patients treated 382 attacks (191 in each group), of which 373 were self-evaluated by the patient, 186 with diclofenac and 187 with placebo. The characteristics of the patients are described in Table 2. Patients in the two treatment groups were comparable with respect to sex, age, duration of migraine history, frequency of attacks, prophylactic drug treatment, proportion of attacks on waking, photophonophobia and all other features shown in Table 2. Efficacy In most cases and more often with placebo (87% of attacks) than with diclofenac (78% of attacks), the patient ingested the second tablet of test medication. The number of attacks aborted within 2 h of the first drug intake and before any escape medication was the main judgement parameter. The treatment was considered as a success if the measure on the visual analogue scale was less than 10 mm 2 h after the first drug intake, or if the attack duration was reported as less than 2 h by the patient, with no escape medication during these 2 h. Whenever an attack was resolved within 2 h, and relapsed within 24 h, it was considered as a treatment failure. Using these criteria, 51 attacks out of the 186 treated with diclofenac aborted in 2 h (27%) and 35 out of the 187 treated with placebo (19%). In the cross-over analysis, 27 patients out of 91 (30%) had more aborted attacks in 2 h with diclofenac than placebo, 13 out of 91 patients (14%) being in the opposite situation (Table 3 and Fig. 1), which shows significant treatment effect (p < 0.05). These results
3 CEPHALALGIA 11 (1991) Oral diclofenac in migraine attacks 61 Table 2. Patient characteristics at inclusion. Group I Group II Total (n = 53) (n = 51) (n = 104) Female/male 41/12 39/12 80/24 Age (years) t 37.5 ± ± ± 11.1 Duration of migraine (years)t 18.7 ± ± ± 11.8 Frequency of attacks/month Total t 4.9 ± ± ± 1.9 Attacks on wakening t 0.8 ± ± ± 0.9 Prophylactic drug treatment 19/53 (36%) 23/51 (45%) 42/104 (40%) Unilateral pain 46/53 (87%) 46/51 (90%) 92/104 (88%) Pulsatility 49/53 (92%) 45/51 (88%) 94/104 (90%) Nausea and/or vomiting 45/53 (85%) 46/50 (92%) 91/103 (88%) Photo and/or phonophobia 41/51 (80%) 42/48 (88%) 83/99 (84%) Familial history of migraine 42/52 (81%) 37/50 (74%) 79/102 (77%) t Mean ± SD Four successive attacks treated in the following order: Group I: Diclofenac - diclofenac - placebo - placebo. Group II: Placebo placebo - diclofenac - diclofenac. No significant difference between the two groups was found on any criterion. Table 3. Main judgement parameter: number of attacks aborted in 2 h. D I Number of Placebo aborted attacks in 2 h Total C L 0 F E N A C Total In this table, patients are classified according to the number of attacks aborted in 2 h with each drug. They have the same results in the diagonal, better results with diclofenac under the diagonal and better results with placebo above the diagonal. were confirmed by the complementary analysis on the 83 patients who treated four attacks with a treatment effect still significant at the 5% level. Results varied greatly between centres, particularly with placebo where the proportion of aborted attacks in 2 h ranged from 7% to 29%. With diclofenac, the success rate ranged from 25% to 39%, with the exception of one centre where no treated attack aborted in 2 h. The intensity of headache evaluated on visual analogue scales was reduced from 52.1 mm (SO 24.0) before treatment to 45.6 mm (27.6) after 2 h for diclofenac and from 53.0 mm (25.5) to 50.5 mm (27.6) for placebo. The difference of 5 mm in favour of diclofenac 2 h after the first drug intake did not reach statistical significance (p = 0.17). Escape medication was taken in 54% of the attacks treated with diclofenac and 66% of those treated with placebo. In the cross-over analysis, 32% of the patients took escape medication less often for diclofenac than for placebo and 11% were in the opposite situation (Fig. 1), which is significant in favour of diclofenac (p < 0.01). The protocol authorized any escape medication with the exclusion of non-steroidal anti-inflammatory drugs (including aspirin). Despite this, salicylates represented 26% of all escape medications, probably because it was the usual treatment. Although it has an impact on criteria such as duration of the attack, it does not interfere with the main parameter: number of attacks aborted in 2 h, i.e. before escape medication. The duration of the attack was on average shorter by 2 h after diclofenac than after placebo, but the difference was not statistically significant in the cross-over analysis (p = 0.08). No statistical difference was found between diclofenac and placebo for the presence of nausea or vomiting which occurred in 40% of the attacks and was shown equally for diclofenac and placebo (Fig. 1). The overall efficacy of the treatment was recorded for each attack by the patient and by the physician on a four points verbal scale (0 = nil, 1 = moderate, 2 = good, 3 = excellent). Diclofenac was scored 0.90 (SO 0.78) by the patient and 1.03 (0.88) by the physician, and placebo 0.62 (0.68) and 0.66 (0.76) respectively. Both evaluations were significantly in favour of diclofenac (p < 0.005) in the cross-over analysis. Safety Safety was evaluated by the physician for the 382 treated attacks. At least one side effect was reported during 26 attacks out of 191 treated with diclofenac (13.6%), and during 18 attacks out of 191 treated with placebo (9.4%) ct test, p = 0.20). Thirty-six symptoms were reported with diclofenac and 23 with placebo, gastrointestinal complaints representing almost half of the symptoms in each group.
4 62 H Massiou et al. CEPHALALGIA 11 (1991) "it of patients * * 32 D>P D=P P>D ABORTED ATTACKS IN 2 HOURS Fig. 1. Proportion of patients in the cross-over analysis according to their compared response between diclofenac (0) and placebo (P). 0> P: Better results under diclofenac than under placebo; 0 = P: Same results under diclofenac and placebo; P > 0: Better results under placebo than under diclofenac; * : p < 0.05 for treatment effect in the cross-over analysis. Three patients dropped out after one or two attacks treated with diclofenac because of nausea and vomiting (1 case), or diarrhoea and abdominal pain (2 cases). In most instances, however, it was difficult to distinguish between a gastrointestinal side effect induced by the drug and the usual accompanying symptoms of migraine. Discussion This study demonstrates that oral diclofenac, administered at an initial dose of 50 mg, with an additional 50 mg if needed, is a well tolerated and effective treatment of migraine attacks. The main parameter of efficacy: the number of attacks aborted within 2 h of drug intake, is now recommended by the International Headache Society, because it is clinically relevant, Simple and not affected by escape medication (16). The latter is of particular relevance since our study indicates that when an escape medication was used, little attention was paid to the specifications of the protocol. Tfelt-Hansen and Olesen (14) stressed that this parameter is a severe one, with low discriminative power. This is confirmed by the rather low percentage of successes observed on this criterion in our trial, the difference between diclofenac and placebo being, however, statistically significant. No previous controlled trial of non-steroidal anti-inflammatory drugs has used this parameter, so any comparison between these studies and ours is impossible. In this trial, diclofenac was significantly more effective than placebo as regards this main criterion and other parameters such as the need for escape medication and the global evaluation of medication. For two other parameters, the intensity of headache after 2 h and the attack duration, a trend towards better results with diclofenac was observed, but statistical significance was not reached. The duration of an attack is a complicated parameter, as it is influenced not only by the test drug but also by the use of escape medication. Headache intensity was recorded in this trial with visual analogue scales on a self-assessment card; investigators reported that some patients forgot to fill in these scales, or did not exactly understand their meaning; it is then possible that the lack of statistical significance is due to unreliable answers of some patients. If such visual scales are used in further studies, they will have to be accompanied by a more precise explanation written on the patient's case report form. Our results indicate that oral diclofenac is worth trying in the treatment of migraine attacks. However, the oral route is not always the best, because of nausea, vomiting and slow gastric emptying accompanying migraine attacks; it might therefore be interesting to test diclofenac suppositories in this indication.
5 CEPHALALGIA 11 (1991) Oral diclofenac in migraine attacks 63 Acknowledgements.-Participating investigators: M. G. Bousser (Hop. Saint-Antoine, Paris), B. Mihout (Rouen), A. Pradalier (Hop. Rothschild, Paris), C Loisy (Vichy), A. Rascol (Hop. Purpan, Toulouse), A. Guillard (Hop. Tenon, Paris), P. Henry (Hop. Pellegrin-Tripode, Bordeaux). References 1. Andersson PG, Hinge HH, Johansen 0, Andersen C, Lademann A, Gotzche PC Double-blind study of naproxen vs placebo in the treatment of acute migraine attack. Cephalalgia 1989;9: Awidi AS. Efficacy of flurbiprofen in the treatment of acute migraine attacks: a double-blind cross-over study. Curr Ther Res 1982;32: Carasso RL, Peled 0, Yehuda S. Flufenamic acid in menstrual migraine. Int J Neurosci 1985;27: Hakkarainen H, Vapaatalo H, Gothoni G, Parantainen J. Tolfenamic acid is as effective as ergotamine during migraine attacks. Lancet 1979;2: Johnson ES, Ratcliffe OM, Wilkinson M. Naproxen sodium in the treatment of migraine. Cephalalgia 1985;5: Kinnunen E, Erkinjuntti T, Farkkila M, Palomaki H, Porras I, Teirmaa H, Freudenthal Y, Andersson P. Placebo controlled double-blind trial of pirprofen and an ergotamine tartrate compound in migraine attacks. Cephalalgia 1988;8: Nestvold K, Kloster R, Partinen M, Sulkava R. Treatment of acute migraine attack: naproxen and placebo compared. Cephalalgia 1985;5: Sacks W. The use of isopyrine-phenylbutazone compound in migraine. SA Med J 1980;58: Sargent JD, Baumel B, Peters K, Diamond S, Saper JR, Eisner LS, Solbach P. Aborting a migraine attack: naproxen sodium v. ergotamine plus caffeine. Headache 1988;28: Tfelt-Hansen P, Olesen J. Effervescent metoclopramide and aspirin (Migravess) versus effervescent aspirin or placebo for migraine attacks: a double-blind study. Cephalalgia 1984; 4: Tokola RA, Kangasniemi P, Neuvonen PI, Tokola 0. Tolfenamic acid, metoclopramide, caffeine and their combinations in the treatment of migraine attacks. Cephalalgia 1984;4: Del Bene E, Poggioni M, Garagiola U, Maresca V. Intramuscular treatment of migraine attacks using diclofenac sodium: a cross-over clinical trial. J Int Med Res 1987;15: Pradalier A, Clapin A, Dry J. Non-steroid anti-inflammatory drugs in the treatment and long-term prevention of migraine attacks. Headache 1988;28: Tfelt-Hansen P, Olesen J. Methodological aspects of drug trials in migraine. Neuroepidemiology 1985;4: Hills M, Armitage P. The two-period cross-over clinical trial. Br J Clin Pharmacol 1979;8: Bousser MG, Baron JC The clinician's view on end points. Neuroepidemiology 1987;6:228-33
Rizatriptan vs. ibuprofen in migraine: a randomised placebo-controlled trial
J Headache Pain (2007) 8:175 179 DOI 10.1007/s10194-007-0386-7 ORIGINAL Usha Kant Misra Jayantee Kalita Rama Kant Yadav Rizatriptan vs. ibuprofen in migraine: a randomised placebo-controlled trial Received:
More informationHeadache Master School Japan-Osaka 2016 (HMSJ-Osaka2016) October 23, II. Management of Refractory Headaches
Headache Master School Japan-Osaka 2016 (HMSJ-Osaka2016) October 23, 2016 II. Management of Refractory Headaches Case presentation 1: A case of intractable daily-persistent headache Keio University School
More informationEffects of migraine attack and metoclopramide on the absorption
Br. J. clin. Pharmac. (1984), 17, 67-75 ffects of migraine attack and metoclopramide on the absorption of tolfenamic acid RIITTA A. TOKOLA & PRTTI J. NUVONN Department of Clinical Pharmacology, University
More informationORIGINAL CONTRIBUTION. Efficacy and Safety of Acetaminophen, Aspirin, and Caffeine in Alleviating Migraine Headache Pain
ORIGINAL CONTRIBUTION Efficacy and Safety of Acetaminophen, Aspirin, and Caffeine in Alleviating Migraine Headache Pain Three Double-blind, Randomized, -Controlled Trials Richard B. Lipton, MD; Walter
More informationZolmitriptan is effective and well tolerated in Japanese patients with migraine: a dose response study
is effective and well tolerated in Japanese patients with migraine: a dose response study F Sakai 1, M Iwata 2, K Tashiro 3, Y Itoyama 4, S Tsuji 5, Y Fukuuchi 6, G Sobue 7, K Nakashima 8 & M Morimatsu
More informationHow do we treat migraine? New SIGN Guidelines
How do we treat migraine? New SIGN Guidelines Managing your migraine Migraine Trust, Edinburgh 2018 Callum Duncan Consultant Neurologist Aberdeen Royal Infirmary Chair SIGN Guideline 155 Premonitory Mood
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationMIGRAINE A MYSTERY HEADACHE
MIGRAINE A MYSTERY HEADACHE The migraine is a chronic neurological disease that is characterized by moderate to severe episodes of headache that is mostly associated with other central nervous system (CNS)
More informationINDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER Volume: Page:
SYNOPSIS Protocol No.: TOPMAT-MIG-303 EudraCT No.: 2005-000321-29 Title of Study: A double-blind, randomised, placebo-controlled, multicentre study to investigate the efficacy and tolerability of in prolonged
More informationComparison of the efficacy and tolerance of isoxicam and piroxicam following surgery for skiing accidents
Br. J. clin. Pharmac. (1986), 22, 161S-165S Comparison of the efficacy and tolerance of isoxicam and piroxicam following surgery for skiing accidents P. MASSART & 'H. BEZES Clinique Chirurgicale et Traumatologique
More informationThe best defense is a good offense. Optimizing the Acute Treatment of Migraine. Disclosures 11/10/2017
Optimizing the Acute Treatment of Migraine Brian M. Plato, DO, FAHS Norton Neuroscience Institute Louisville, KY Disclosures Speakers Bureau (personal): Allergan, Depomed, Avanir Research Funding (paid
More informationManagement options for Migraine. Prof. Dr. Khwaja Nazimuddin Head Dept. of Internal Medicine BIRDEM
Management options for Migraine Prof. Dr. Khwaja Nazimuddin Head Dept. of Internal Medicine BIRDEM Assessment The Migraine Disability Assessment Score MIDAS Complete loss of work Partial loss of work Off
More informationAna Podgorac Belgrade, May 2012
Headache and reproductive life Ana Podgorac Belgrade, May 2012 52 years old woman, English teacher in primary school, married, mother of two, with a history of migraine without aura. Over the last 6 months
More informationGuidelines for controlled trials of drugs in migraine: second edition
Guidelines for controlled trials of drugs in migraine: second edition International Headache Society Clinical Trials Subcommittee. Committee members: P Tfelt-Hansen (Chairman) (Denmark), G Block (USA),
More informationJessica Ailani MD FAHS Director, Georgetown Headache Center Associate Professor Neurology Medstar Georgetown University Hospital
Jessica Ailani MD FAHS Director, Georgetown Headache Center Associate Professor Neurology Medstar Georgetown University Hospital Honorarium from Current Pain and Headache Reports; Section Editor Unusual
More informationChronic Migraine in Primary Care. December 11 th, 2017 Werner J. Becker University of Calgary
Chronic Migraine in Primary Care December 11 th, 2017 Werner J. Becker University of Calgary Disclosures Faculty: Werner J. Becker Relationships with commercial interests: Grants/Research Support: Clinical
More informationExtended Abstracts: Naproxen
Primary Literature 1) Prior MJ, Cooper KM, May LG, Bowen DL. Efficacy and safety of acetaminophen and naproxen in the treatment of tension-type headache. A randomized, double-blind, placebo-controlled
More informationAbstract The aim of this prospective,
J Headache Pain (2005) 6:143 148 DOI 10.1007/s10194-005-0169-y ORIGINAL Zulfi Engindeniz Celaleddin Demircan Necdet Karli Erol Armagan Mehtap Bulut Tayfun Aydin Mehmet Zarifoglu Intramuscular tramadol
More informationThe 45-year-old woman with monthly headaches. Anne MacGregor Barts and the London School of Medicine and Dentistry
The 45-year-old woman with monthly headaches Anne MacGregor Barts and the London School of Medicine and Dentistry Learning Objectives Use of diary cards for establishing patterns of attacks Importance
More informationADVANCES IN MIGRAINE MANAGEMENT
ADVANCES IN MIGRAINE MANAGEMENT Joanna Girard Katzman, M.D.MSPH Assistant Professor, Dept. of Neurology Project ECHO, Chronic Pain Program University of New Mexico Outline Migraine throughout the decades
More informationThe use of combination therapies in the acute management of migraine
REVIEW The use of combination therapies in the acute management of migraine Abouch Valenty Krymchantowski Headache Center of Rio, Rio de Janeiro, Brazil; Outpatient Headache Unit of the Instituto de Neurologia
More informationMigraine much more than just a headache
Migraine much more than just a headache Session hosted by Teva UK Limited PUU4 11:15 12:15 UK/NHSS/18/0021b Date of Preparation: August 2018 The views expressed in this presentation are those of the speaker
More informationTreatment Of Medication. Overuse Headache
7 November 2012 BASH GPwSI Meeting Lecture title... Treatment Of Medication Dr... Overuse Headache Dr Marcus Lewis Dr... The National Migraine Centre International Headache Society Diagnostic criteria
More informationSpecific Care Question : Question Originator: Plain Language Summary from The Office of Evidence Based Practice: Conditional Recommendation
Ketorolac for Refractory Migraine in the ED Specific Care Question : In the pediatric patient diagnosed with refractory migraine is ketorolac an effective treatment? Question Originator: Migraine Therapy
More informationFaculty Disclosures. Learning Objectives. Acute Treatment Strategies
WWW.AMERICANHEADACHESOCIETY.ORG Acute Treatment Strategies Content developed by: Lawrence C. Newman, MD, FAHS Donna Gutterman, PharmD Faculty Disclosures LAWRENCE C. NEWMAN, MD, FAHS Dr. Newman has received
More informationSponsor. Generic Drug Name. Trial Indication(s) Protocol Number. Protocol Title. Clinical Trial Phases. Study Start/End Dates
Sponsor Novartis Generic Drug Name Lumiracoxib Trial Indication(s) Safety study effects on small bowel Protocol Number CCOX189A2425 Protocol Title A 16-day, randomized, double-blind, double-dummy, placebo-controlled,
More informationPrednisone vs. placebo in withdrawal therapy following medication overuse headache
doi:10.1111/j.1468-2982.2007.01488.x Prednisone vs. placebo in withdrawal therapy following medication overuse headache L Pageler 1,2, Z Katsarava 2, HC Diener 2 & V Limmroth 1,2 1 Department of Neurology,
More informationHoofdpijn in de apotheek
Hoofdpijn in de apotheek Prof. Dr. Koen Paemeleire Dienst Neurologie, Universitair Ziekenhuis Gent Vakgroep Medische Basiswetenschappen, Universiteit Gent Overzicht 1. Epidemiologie 2. Red flags 3. Medication-overuse
More informationDose: Metoclopramide -0.1 mg/kg (max 10 mg) IV, over 15 minutes
Metoclopramide for Refractory Migraine in the ED Specific Care Question : In the pediatric patient diagnosed with refractory migraine, is metoclopramide an effective treatment? Question Originator: Migraine
More informationChildren Enteric coated tablet : 1-3 mg/kg per day in divided doses.
Ultrafen Tablet/SR Tablet/Suppository/Gel Description Ultrafen is a preparation of Diclofenac is a non-steroidal antiinflammatory agent with marked analgesic, anti-inflammatory and antipyretic properties.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationACUTE TREATMENT FOR MIGRAINE. Cristina Tassorelli
The European Headache School 2012 ACUTE TREATMENT FOR MIGRAINE Cristina Tassorelli Headache Science Centre, IRCCS Neurological Institute C. Mondino Foundation - Pavia University Centre for Adaptive Disorders
More informationPain therapeutics. Acetaminophen/NSAIDs Acute pain Osteoarthritis Migraine Acute Gout Neuropathic pain
Pain therapeutics Acetaminophen/NSAIDs Acute pain Osteoarthritis Migraine Acute Gout Neuropathic pain James McCormack, Pharm.D. Professor Faculty of Pharmaceutical Sciences, UBC Common types of pain killers
More informationGastrointestinal Tolerability of Ibuprofen Compared with Paracetamol and Aspirin at Over-the-counter Doses
The Journal of International Medical Research 2002; 30: 301 308 Gastrointestinal Tolerability of Ibuprofen Compared with Paracetamol and Aspirin at Over-the-counter Doses P RAMPAL 1, N MOORE 2, E VAN GANSE
More informationVenlafaxine versus amitriptyline in the prophylactic treatment of migraine: randomized, double-blind, crossover study
Clinical Neurology and Neurosurgery 107 (2004) 44 48 Venlafaxine versus amitriptyline in the prophylactic treatment of migraine: randomized, double-blind, crossover study Serpil Bulut a,, M. Said Berilgen
More informationTHE WOMAN WHO COULD NOT DECIDE WHICH MEDICATION TO TAKE
Rapoport Ch 05.qxd 10/15/08 1:06 PM Page 25 CHAPTER 5 THE WOMAN WHO COULD NOT DECIDE WHICH MEDICATION TO TAKE ALLAN PURDY, MD, FRCPC FRED SHEFTELL, MD ALAN RAPOPORT, MD STEWART J. TEPPER, MD Case History
More informationPHARMACY COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 5/18/17 SECTION: DRUGS LAST REVIEW DATE: 5/17/18 LAST CRITERIA REVISION DATE: ARCHIVE DATE:
ALLZITAL (butalbital and acetaminophen) 25 mg/325 mg oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific
More informationOVERVIEW OF COMMENTS RECEIVED ON DRAFT GUIDELINE ON CLINICAL INVESTIGATION OF MEDICINAL PRODUCTS FOR THE TREATMENT OF MIGRAINE
European Medicines Agency London, 24 January 2007 Doc. Ref. EMEA/CHMP/EWP/21477/2007 OVERVIEW OF COMMENTS RECEIVED ON DRAFT GUIDELINE ON CLINICAL INVESTIGATION OF MEDICINAL PRODUCTS FOR THE TREATMENT OF
More informationtrial of celecoxib in the treatment of
Original Article Singapore Med 1 2007, 48 (9) : 834 Randomised, open label, controlled trial of celecoxib in the treatment of acute migraine Loo C Y, Tan H J, Teh H S, Raymond A A Neurology Unit, Department
More informationRecognition and treatment of medication overuse headache
Recognition and treatment of medication overuse headache Marcus Lewis MA, MRCGP, DRCOG, DFSRH 20 Mean weekly headache index 15 10 5 Medication overuse headache is a common condition responsible for a high
More informationDisclosures. Triptans for Kids 5/16/13
5/16/13 Disclosures Triptans for Kids Amy A. Gelfand, MD GelfandA@neuropeds.ucsf.edu Departments of Neurology and Pediatrics UCSF Child Neurology and Headache Center I receive grant funding from: NIH/NINDS
More informationCEPMAGH. Optimal routes of administration of ergotamine tartrate in-cluster headache patients. A pharmacokinetic study* Introduction
Optimal routes of administration of ergotamine tartrate in-cluster headache patients. A pharmacokinetic study* K. Ekbom, A. E. Krabbe, G. Paalzow, L. Paalzow, P. Tfelt-Hansen and E. Waldenlind CEPMAGH
More informationDespite the widespread use of triptans ... REPORTS... Almotriptan: A Review of Pharmacology, Clinical Efficacy, and Tolerability
... REPORTS... Almotriptan: A Review of Pharmacology, Clinical Efficacy, and Tolerability Randal L. Von Seggern, PharmD, BCPS Abstract Objective: This article summarizes preclinical and clinical data for
More informationHMFP Comprehensive Headache Center Department of Anesthesia, Critical Care and Pain Medicine Beth Israel Deaconess Medical Center Instructor in
HMFP Comprehensive Headache Center Department of Anesthesia, Critical Care and Pain Medicine Beth Israel Deaconess Medical Center Instructor in Anesthesia and Neurology Harvard Medical School Limited time
More informationThursday, April 25, 13. Intervention Studies
Intervention Studies Outline Introduction Advantages and disadvantages Avoidance of bias Parallel group studies Cross-over studies 2 Introduction Intervention study, or clinical trial, is an experiment
More informationHEADACHE: Types, Tips & Treatment Suggestions
Headaches are one of the most common complaints patients present with in primary care settings. They are often correlated with stress, tension and a litany of existing medical conditions. Often, patients
More informationStudy No.:MPX Title: Rationale: Phase: IIB Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationMigraine Types and Triggering Factors in Children
original ARTICLE Migraine Types and Triggering Factors in Children How to Cite this Article: Nejad Biglari H, Karimzadeh P, Mohammadi Kord-kheyli M, Hashemi SM. Migraine Types and Triggering Factors in
More informationZolmitriptan nasal spray provides fast relief of migraine symptoms and is preferred by patients: a Swedish study of preference in clinical practice
J Headache Pain (2004) 5:237 242 DOI 10.1007/s10194-004-0132-3 ORIGINAL Carl G.H. Dahlöf Mattias Linde Erika Kerekes Zolmitriptan nasal spray provides fast relief of migraine symptoms and is preferred
More informationEletriptan vs sumatriptan: A double-blind, placebo-controlled, multiple migraine attack study
Eletriptan vs sumatriptan: A double-blind, placebo-controlled, multiple migraine attack study G. Sandrini, M. Färkkilä, G. Burgess, et al. Neurology 2002;59;1210-1217 DOI 10.1212/WNL.59.8.1210 This information
More informationRiboflavin: An Alternative Approach to Managing Migrane Attacks in the Adult Population
UCLA Nutrition Bytes Title : An Alternative Approach to Managing Migrane Attacks in the Adult Population Permalink https://escholarship.org/uc/item/2rd9m4j0 Journal Nutrition Bytes, 14(1) ISSN 1548-601X
More informationÇiçek Wöber-Bingöl HEADACHE UNIT FOR CHILDREN AND ADOLESCENCE
Headache in children and adolescents Çiçek Wöber-Bingöl HEADACHE UNIT FOR CHILDREN AND ADOLESCENCE Dept. of Psychiatry of Childhood and Adolescence Medical University of Vienna, Vienna, Austria Impact
More informationDoes repeated subcutaneous administration of sumatriptan produce an unfavorable evolution in cluster headache?
J Headache Pain (2004) 5:110 114 DOI 10.1007/s10194-004-0078-5 ORIGINAL Virginie Dousset Virginie Chrysostome Bruno Ruiz S. Irachabal Magalie Lafittau Françoise Radat Bruno Brochet Patrick Henry Does repeated
More informationDrug Class Review on Triptans
Drug Class Review on UPDATED FINAL REPORT #1 December 2003 Mark Helfand, MD, MPH Kim Peterson, MS Oregon Evidence-based Practice Center Oregon Health & Science University Table of Contents Introduction
More informationA French, multicentre, placebo-controlled, randomised, double-blind,
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinialTrials.gov
More informationDrug Class Review on the Triptans
Drug Class Review on the Final Report March 7, 2003 Expires October 31, 2003 Mark Helfand, MD, MPH Kim Peterson, MS Produced by Oregon Health & Science University 3181 SW Sam Jackson Park Road Mailcode:
More informationHEADACHE: Benign or Severe Dr Gobinda Chandra Roy
HEADACHE: Benign or Severe Dr Gobinda Chandra Roy Associate Professor, Department of Medicine, Shaheed Suhrawardy Medical College and Hospital Outlines 1. Introduction 2. Classification of headache 3.
More information10/17/2017 CHRONIC MIGRAINES BOTOX: TO INJECT OR NOT INJECT? IN CHRONIC MIGRAINE PROPHYLAXIS OBJECTIVES PATIENT CASE EPIDEMIOLOGY EPIDEMIOLOGY
BOTOX: TO INJECT OR NOT INJECT? IN CHRONIC MIGRAINE PROPHYLAXIS OBJECTIVES JENNIFER SHIN, PHARMD PGY2 AMBULATORY CARE PHARMACY RESIDENT COMMUNITYCARE HEALTH CENTERS PHARMACOTHERAPY ROUNDS OCTOBER 20, 2017
More informationThursday, April 25, 13. Intervention Studies
Intervention Studies Outline Introduction Advantages and disadvantages Avoidance of bias Parallel group studies Cross-over studies 2 Introduction Intervention study, or clinical trial, is an experiment
More informationUpdate on Diagnosis and Management of Migraines
Update on Diagnosis and Management of Migraines Joel J. Heidelbaugh, MD, FAAFP, FACG Clinical Professor Departments of Family Medicine and Urology University of Michigan Learning Objectives To distinguish
More informationWORTH A CLOSER LOOK.
A birth control pill... WORTH A CLOSER LOOK. Ask your healthcare provider about. Please see Important Safety Information including Boxed Warning throughout this brochure and on pages 4 and 5. offers a
More informationA trial of opipramol in the treatment of migraine
Journal of Neurology, Neurosurgery, and Psychiatry, 1972, 35, 500-504 A trial of opipramol in the treatment of migraine HARRY JACOBS From Severalls Hospital, Colchester SUMMARY A double blind trial of
More information...SELECTED ABSTRACTS...
The following abstracts, from medical journals containing literature on migraine management, were selected for their relevance to this Special Report supplement. Two Sumatriptan Studies Two double-blind
More informationManagement of headache
Management of headache TJ Steiner Imperial College London Based on European principles of management of common headache disorders TJ Steiner, K Paemeleire, R Jensen, D Valade, L Savi, MJA Lainez, H-C Diener,
More informationMigraine: Developing Drugs for Acute Treatment Guidance for Industry
Migraine: Developing Drugs for Acute Treatment Guidance for Industry U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) February 2018
More informationTABLE 1. Current Diagnostic Criteria for Migraine Without Aura 2 A. At least 5 attacks fulfilling criteria B-D B. Headache attacks lasting 4-72 hours
ANSWERS CONCISE TO FREQUENTLY REVIEW ASKED QUESTIONS FOR CLINICIANS ABOUT MIGRAINE Answers to Frequently Asked Questions About Migraine IVAN GARZA, MD, AND JERRY W. SWANSON, MD Migraine is a common primary
More informationThe effects of acetylsalicylic acid on swelling, pain and other
Br. J. clin. Pharmac. (1984), 17, 379-384 The effects of acetylsalicylic acid on swelling, pain and other events after surgery P. SKJELBRED Institute of Pharmacology, and Department of Oral Surgery and
More informationClinical Study Synopsis
Clinical Study Synopsis This document is not intended to replace the advice of a healthcare professional and should not be considered as a recommendation. Patients should always seek medical advice before
More informationAdult & Pediatric Patients. Stanford Health Care, Division Pain Medicine
Acute Treatment Strategies in Adult & Pediatric Patients Theresa Mallick Searle, MS, RN BC, ANP BC Disclosures Speakers Bureau: Allergan, Depomed Acute Treatment Strategies in Adult & Pediatric Patients
More informationApplication of ICHD 2nd edition criteria for primary headaches with the aid of a computerised, structured medical record for the specialist
J Headache Pain (2005) 6:205 210 DOI 10.1007/s10194-005-0186-x ICHD-II: EVALUATION AND PROPOSALS Paola Sarchielli Mauro Pedini Andrea Alberti Cristiana Rossi Antonio Baldi Ilenia Corbelli Paolo Calabresi
More informationAdvances in the Treatment of Migraine
Advances in the Treatment of Migraine C. Philip O Carroll, M.D. Director Neurobehavioral Medicine Hoag Neurosciences Institute Guyuron B Headache, 2015;55:1464-1473 I m sorry your head hurts, sweetie.is
More informationI have no financial relationships to disclose. I will not discuss investigational use of medication in my presentation.
I have no financial relationships to disclose. I will not discuss investigational use of medication in my presentation. In 1962, Bille published landmark epidemiologic survey of headache among 9,000 school
More informationOBSTETRICS & GYNECOLOGY
DECEMBER 2011 NORLAND AVENUE PHARMACY PRESCRIPTION COMPOUNDING N ORLANDA VENUEP HARMACY. COM We customize individual prescriptions for the specific needs of our patients. INSIDE THIS ISSUE: Migraine Headache
More informationMedication For Migraine Chart: Table 1: Acute Treatment when the attack begins
Medication For Migraine Chart: Table 1: Acute Treatment when the attack begins Page a Analgesics (painkillers) Non-steroidal antiinflammatory drugs (NSAIDs) Prescription required Brand Name Formulation
More informationSpecific features of migraine syndrome in children
J Headache Pain (2006) 7:206 210 DOI 10.1007/s10194-006-0312-4 RAPID COMMUNICATION Marija Knezevic-Pogancev Specific features of migraine syndrome in children Received: 16 April 2006 Accepted in revised
More informationPreventive Effect of Greater Occipital Nerve Block on Severity and Frequency of Migraine Headache
Proceeding S.Z.P.G.M.I. Vol: 31(2): pp. 75-79, 2017. Preventive effect of Greater Occipital Nerve Block on Severity and Frequency of Migraine Headache Dr. Syed Mehmood Ali, Dr. Mudassar Aslam, Dr. Dawood
More informationPaediatric headaches. Dr Jaycen Cruickshank Director of Clinical Training Ballarat Health Services. Brevity, levity, repetition
Paediatric headaches Dr Jaycen Cruickshank Director of Clinical Training Ballarat Health Services Brevity, levity, repetition Paediatric)headache?)! Headache!in!children!is!not!that!common.!The!question!is!which!headaches!do!I!
More informationClinical Trials. Hans-Christoph Diener Senior Professor of Clinical Neuroscienes Medical Faculty University Duisburg-Essen Germany
Clinical Trials Hans-Christoph Diener Senior Professor of Clinical Neuroscienes Medical Faculty University Duisburg-Essen Germany Conflict of Interest Statement German Research Council German Ministry
More informationPublic Assessment Report Scientific discussion. Aspirin (acetylsalicylic acid) Asp no:
Public Assessment Report Scientific discussion Aspirin (acetylsalicylic acid) Asp no: 2015-0454 This module reflects the scientific discussion for the approval of Aspirin. The procedure was finalised on
More informationANTIMIGRAINE MEDICINES
1 07.00.00.00 - ANTIMIGRAINE MEDICINES 1. Summary statement For acute migraine therapy the following new medicine is proposed: Sumatriptan 50 mg. 2. 3. Global Campaign to Reduce the Burden of Headache
More informationORIGINAL ARTICLE INTRODUCTION
ORIGINAL ARTICLE The Efficacy of Propofol vs. Subcutaneous Sumatriptan for Treatment of Acute Migraine Headaches in the Emergency Department: A Double-Blinded Clinical Trial Hossein Moshtaghion, MD*; Najmeh
More informationNew Medicine Report (Adopted by the CCG until review and further
New Medicine Report (Adopted by the CCG until review and further DEXIBUPROFEN notice) Document Status Decision made at Suffolk D&TC 7 th September 2006 Traffic Light Decision Double Green Prescriber s
More informationCinnarizine versus Topiramate in Prophylaxis of Migraines among Children and Adolescents: A Randomized, Double-Blind Clinical Trial
original ARTICLE Cinnarizine versus Topiramate in Prophylaxis of Migraines among Children and Adolescents: A Randomized, Double-Blind Clinical Trial How to Cite This Article: Ashrafi MR, Najafi Z, Shafiei
More informationEpidemiology of headache and migraine in women
J. Neurol. Neurosurg. Psychiat., 1971, 34, 148-153 Epidemiology of headache and migraine in women W. E. WATERS' AND P. J. O'CONNOR From the Medical Research Council Epidemiology Unit (South Wales), Cardiff,
More informationAdult with headache. Problem-specific video guides to diagnosing patients and helping them with management and prevention
Adult with headache Problem-specific video guides to diagnosing patients and helping them with management and prevention London Strategic Clinical Networks London Neuroscience Strategic Clinical Network
More informationIs Yoga an Effective Treatment for Reducing the Frequency of Episodic Migraine?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2018 Is Yoga an Effective Treatment for Reducing
More informationGuidance for Industry Migraine: Developing Drugs for Acute Treatment
Guidance for Industry Migraine: Developing Drugs for Acute Treatment DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this draft
More informationAcute Migraine Treatment: What you and your family should know to help you make the best choices with your doctor
Acute Migraine Treatment: What you and your family should know to help you make the best choices with your doctor TAKE CONTROL OF YOUR MIGRAINES! ABOUT THIS PATIENT GUIDE: Migraine attacks are often debilitating
More informationA new questionnaire for assessment of adverse events associated with triptans: methods of assessment influence the results. Preliminary results
J Headache Pain (2004) 5:S112 S116 DOI 10.1007/s10194-004-0123-4 Michele Feleppa Fred D. Sheftell Luciana Ciannella Amedeo D Alessio Giancarlo Apice Nino N. Capobianco Donato M.T. Saracino Walter Di Iorio
More informationAndrew J. Dowson Hélène Massiou Sheena K. Aurora
J Headache Pain (2005) 6:81 87 DOI 10.1007/s10194-005-0156-3 ORIGINAL Andrew J. Dowson Hélène Massiou Sheena K. Aurora Managing migraine headaches experienced by patients who self-report with menstrually
More informationPIRPROFEN IN TREATMENT OF NON-ARTICULAR RHEUMATISM IN PAKISTANI OUTPATIENTS, A MULTICENTRE STUDY
Abstract PIRPROFEN IN TREATMENT OF NON-ARTICULAR RHEUMATISM IN PAKISTANI OUTPATIENTS, A MULTICENTRE STUDY Pages with reference to book, From 265 To 268 N,A.Jaffer ( Ciba-Geigy (Pakistan) Limited, Karachi.
More informationAtenolol in the prophylaxis of chronic migraine: a 3-month open-label study
Edvardsson SpringerPlus 2013, 2:479 a SpringerOpen Journal RESEARCH Open Access Atenolol in the prophylaxis of chronic migraine: a 3-month open-label study Bengt Edvardsson Abstract Background: Chronic
More informationA double blind multicentre trial with BRONCHO-VAXOM in adults
Published in Atemwegs- und Lungenkrankheiten, 9 : 424427, 1983 A double blind multicentre trial with BRONCHO-VAXOM in adults J. AHRENS Objective Evaluation of the long-term effectiveness of BRONCHO-VAXOM
More informationModel-based quantification of the relationship between age and anti-migraine therapy
6 Model-based quantification of the relationship between age and anti-migraine therapy HJ Maas, M Danhof, OE Della Pasqua Submitted to BMC. Clin. Pharmacol. Migraine is a neurological disease that affects
More informationTRANSPARENCY COMMITTEE OPINION. 26 November 2008
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 26 November 2008 CHONDROSULF 400 mg, capsule Box containing 84 capsules (CIP: 335 917-3) CHONDROSULF 400 mg, granules
More informationTreatment satisfaction with zolmitriptan nasal spray for migraine in a real life setting: results from phase two of the REALIZE study
J Headache Pain (2005) 6:405 411 DOI 10.1007/s10194-005-0237-3 ORIGINAL Marek Gawel Jürgen Aschoff Arne May Bruce R. Charlesworth on behalf of the REALIZE Study Group Treatment satisfaction with zolmitriptan
More informationClinical Trial Study Synopsis
Clinical Trial Study Synopsis This file is posted on the Bayer HealthCare Clinical Trials Registry and Results website and is provided for patients and healthcare professionals to increase the transparency
More informationIbuprofen versus other non-steroidal anti-in ammatory drugs: use in general practice and patient perception
Aliment Pharmacol Ther 2000; 14: 187±191. Ibuprofen versus other non-steroidal anti-in ammatory drugs: use in general practice and patient perception C. J. HAWKEY 1,D.J.E.CULLEN 1,9,G.PEARSON 1,S.HOLMES
More informationNational Hospital for Neurology and Neurosurgery. Migraine Associated Dizziness. Department of Neuro-otology
National Hospital for Neurology and Neurosurgery Migraine Associated Dizziness Department of Neuro-otology If you would like this document in another language or format or if you require the services of
More informationPatient Information Leaflet Lodine* SR Tablets 600mg (etodolac) 1. WHAT LODINE SR TABLETS ARE AND WHAT THEY ARE USED FOR
Patient Information Leaflet Lodine* SR Tablets 600mg (etodolac) Read all of this leaflet carefully before you start using this medicine. Keep this leaflet. You may need to read it again. If you have any
More information